Fortitude Family Office’s Intellia Therapeutics NTLA Stock Holding History

Fortitude Family Office’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.46K	Hold	370	–	–	﹤0.01%	1627
2026 Q2	$6.26K	Buy	370 +253	+216%	+$3.54K	﹤0.01%	973
2026 Q1	$1.5K	Buy	+117	New	+$1.49K	﹤0.01%	1381
2025 Q4	–	Sell	-74	Closed	-$1.28K	–	2059
2025 Q3	$1.28K	Hold	74	–	–	﹤0.01%	1447
2025 Q2	$694	Buy	+74	New	+$608	﹤0.01%	1662

Other funds holding NTLA

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $416M AUM 11.87% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return

CWP

Cyndeo Wealth Partners St. Petersburg, Florida $2.21B AUM 17.29% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

LAM

Lewis Asset Management Lafayette, California $294M AUM 25.62% 1-Year Est. Return

Independent Financial Group San Diego, California $5.51B AUM 33.52% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Fortitude Family Office's NTLA Position: Q3 2026 in Review

Fortitude Family Office held its Intellia Therapeutics (NTLA) position steady in Q3 2026 at 370 shares worth $4.46K. The position accounts for ﹤0.01% of the portfolio, ranked #1627.

Fortitude Family Office first reported a position in NTLA in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.26K in Q2 2026. 22 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

Fortitude Family Office held 370 shares of Intellia Therapeutics worth $4.46K as of Q3 2026.
Fortitude Family Office left its Intellia Therapeutics share count unchanged in Q3 2026.
Intellia Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1627 holding.
Fortitude Family Office first reported a position in Intellia Therapeutics in Q2 2025 and has held it in 5 quarters since.
Fortitude Family Office's Intellia Therapeutics position peaked at $6.26K in Q2 2026.
22 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.